Targeting DHHC21 may be therapeutically beneficial for ALPS and diseases associated with deregulated activation of STIM1, such as tubular aggregate myopathy and Stormorken syndrome. Here, STIM1 is linked to autoimmune lymphoproliferative syndrome.